Leflunomide vs placebo, 6 months
For outcome · patients with rheumatoid arthritis in adults
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
15 questions · 15 findings · 2 reviews · Musculoskeletal
No studies found 2 · 13.3%GRADE not reported 0 · 0%Very low 4 · 26.7%Low 0 · 0%Moderate 1 · 6.7%High 8 · 53.3%
Leflunomide vs placebo, 6 months
ACR 50 response at 6 months · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide leads to higher ACR 50 response at 6 months compared with placebo, 6 months (high certainty).
1 finding from 1 review
- RR 2.32 [1.32, 4.05]1 study · 221 participantsHigh
Leflunomide vs placebo, 6 months
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
1 finding from 1 review
- no estimate extracted3 studies · 679 participantsHigh
Leflunomide vs placebo, 6 months
Pain change (0‐100 mm VAS) · patients with rheumatoid arthritis in adults
1 finding from 1 review
- no estimate extracted3 studies · 724 participantsHigh
Leflunomide vs placebo, 6 months
Radiographic joint changes · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide showed no clear difference in radiographic change (Change in Sharp score) compared with placebo, 6 months (high certainty).
1 finding from 1 review
- RR 1.23 [0.91, 1.66]1 study · 380 participantsHigh
Leflunomide vs placebo, 6 months
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review
- no estimate extracted3 studies · 727 participantsHigh
Summary of findings: leflunomide + methotrexate vs methotrexate
Change in pain (0‐100 mm VAS) · patients with rheumatoid arthritis in adults
1 finding from 1 review
- no estimate extracted1 study · 263 participantsHigh
Summary of findings: leflunomide + methotrexate vs methotrexate
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review
- no estimate extracted1 study · 263 participantsModerate
Summary of findings: leflunomide + methotrexate vs methotrexate
For outcome · patients with rheumatoid arthritis in adults
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings: leflunomide + methotrexate vs methotrexate
ACR 50% improvement · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide + methotrexate leads to higher ACR 50 at 6 months compared with methotrexate, 6 months (high certainty).
1 finding from 1 review
- RR 4.35 [2.09, 9.03]1 study · 263 participantsHigh
Summary of findings: leflunomide + methotrexate vs methotrexate
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
1 finding from 1 review
- no estimate extracted1 study · 263 participantsHigh
Methotrexate vs other DMARDs
Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis
1 finding from 1 review
- no estimate extracted2 studies · 61 participantsVery low
Methotrexate vs other DMARDs
Withdrawals due to adverse events · psoriatic arthritis
1 finding from 1 review
- no estimate extracted2 studies · 61 participantsVery low
Methotrexate vs other DMARDs
Disease response (leflunomide) · psoriatic arthritis
It is very uncertain whether methotrexate changes disease response (leflunomide) compared with other DMARDs (very low certainty).
1 finding from 1 review
- RR 1.05 [0.77, 1.45]1 study · 30 participantsVery low
Methotrexate vs other DMARDs
Function (leflunomide) · psoriatic arthritis
1 finding from 1 review
- no estimate extracted1 study · 31 participantsVery low